Detail Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients (from Journal of Immunology Research 2015) Bibliografi Author: Yutani, Shigeru ; Ueshima, Kazuomi ; Abe, Kazumichi ; Ishiguro, Atsushi ; Eguchi, Junichi ; Matsueda, Satoko ; Komatsu, Nobukazu ; Shichijo, Shigeki ; Yamada, Akira ; Itoh, Kyogo ; Sasada, Tetsuro ; Kudo, Masatoshi ; Noguchi, Masanori Topik: Personalized peptide vaccination; Hepatitis C virus; Seminar - Thesis lit Bahasa: (EN )     Penerbit: Hindawi Publishing Corporation     Tempat Terbit: New York    Tahun Terbit: 2015     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: JIR2015-473909.pdf (705.02KB; 0 download) Abstract Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study.Amaximumof fourHLA-matched peptideswere selected based on the preexisting IgGresponses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35–44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patientswere enrolled.Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction. [seminar - thesis lit] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved